Ravi Kiran Ghanta

Ravi Kiran Ghanta

Auto-generated profile, based on publicly available information

Ravi Kiran Ghanta

Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
RSRohan M. Shah
Rohan M. Shah
QZQianzi Zhang
Qianzi Zhang
SCSubhasis Chatterjee
Subhasis Chatterjee
FCFaisal Cheema
Faisal Cheema
GLGabriel Loor
Gabriel Loor
RGRavi K. Ghanta
Ravi K. Ghanta

3 October 2022 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
CRChristopher T. Ryan
Christopher T. Ryan
ZZZijian Zeng
Zijian Zeng
SCSubhasis Chatterjee
Subhasis Chatterjee
MWMatthew J. Wall
Matthew J. Wall
MMMarc R. Moon
Marc R. Moon
RGRavi K. Ghanta
Ravi K. Ghanta

15 September 2020 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
RGRavi K. Ghanta
Ravi K. Ghanta
SASamira Aghlara-Fotovat
Samira Aghlara-Fotovat
APAarthi Pugazenthi
Aarthi Pugazenthi
CRChristopher T. Ryan
Christopher T. Ryan
VSVivek P. Singh
Vivek P. Singh
OVOmid Veiseh
Omid Veiseh
Paracrine factors secreted by mesenchymal stem cells (MSCs) have been previously shown to improve cardiac function following acute myocardial infarction (MI). However, cell therapy activates the innate immune response, leading to the rapid elimination of transplanted cells and only short-term therapeutic delivery. Herein, we describe a new strategy to deliver sustained paracrine-mediated MSC therapy to ischemic myocardium. Using an immune evasive, small molecule modified alginate, we encapsulated rat MSC cells in a core–shell hydrogel capsule and implanted them in the pericardial sac of post-MI rats. Encapsulated cells allowed diffusion of reparative paracrine factors at levels similar to non-encapsulated cells in vitro. Encapsulation enabled sustained cell survival with localization over the heart for 2 weeks. The effect of the experimental group on ventricular function and fibrosis was compared with blank (cell free) capsules and unencapsulated MSCs injected into infarcted myocardium. MSC capsules improved post-MI ventricular function ∼2.5× greater than MSC injection. After 4 weeks, post-MI fibrosis was reduced ∼2/3 with MSC capsules, but unchanged with MSC injection. MSC encapsulation with alginate core–shell capsules sustains cell survival and potentiates efficacy of therapy.

15 May 2023 in Respiratory Medicine
Verified
Journal Article
Closed access
BMBabith J. Mankidy
Babith J. Mankidy
MGMohammad Ghasemi-rad
Mohammad Ghasemi-rad
KTKelly Trinh
Kelly Trinh
AAAnoop Padoor Ayyappan
Anoop Padoor Ayyappan
QHQuillan Huang
Quillan Huang
DLDonald R. Lazarus
Donald R. Lazarus

Verified
Journal Article
Open access
PDF file
PVPremakumari Venkatesh
Premakumari Venkatesh
JPJulie Phillippi
Julie Phillippi
SCSasanka Chukkapalli
Sasanka Chukkapalli
MRMercedes Rivera-Kweh
Mercedes Rivera-Kweh
IVIrina Velsko
Irina Velsko
KLKesavalu Lakshmyya
Kesavalu Lakshmyya
Altered microRNA expression is implicated in cardiovascular diseases. Our objective was to determine microRNA signatures in thoracic aortic aneurysms (TAAs) and abdominal aortic aneurysms (AAAs) compared with control non-aneurysmal aortic specimens. We evaluated the expression of fifteen selected microRNA in human TAA and AAA operative specimens compared to controls. We observed significant upregulation of miR-221 and downregulation of miR-1 and -133 in TAA specimens. In contrast, upregulation of miR-146a and downregulation of miR-145 and -331-3p were found only for AAA specimens. Upregulation of miR-126 and -486-5p and downregulation of miR-30c-2*, -155, and -204 were observed in specimens of TAAs and AAAs. The data reveal microRNA expression signatures unique to aneurysm location and common to both thoracic and abdominal pathologies. Thus, changes in miR-1, -29a, -133a, and -221 are involved in TAAs and miR-145, -146, and -331-3p impact AAAs. This work validates prior studies on microRNA expression in aneurysmal diseases.

1 September 2022 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
RZRodrigo Zea-Vera
Rodrigo Zea-Vera
CRChristopher T. Ryan
Christopher T. Ryan
JHJim Havelka
Jim Havelka
SCStuart J. Corr
Stuart J. Corr
TNTom C. Nguyen
Tom C. Nguyen
RGRavi K. Ghanta
Ravi K. Ghanta